Product Information
EVOTAZ 300 MG-150 MG TABLET is a brand product labeled by E.R. Squibb & Sons, L.L.C., priced at $52.0479 per EA under NDC 00003364111. Its NADAC has been published 555 times since Jun 17, 2015.
FDA first approved this application on Jan 29, 2015.
Strength
300; 150 mg/1; mg/1
Manufacturer
E.R. Squibb & Sons, L.L.C.NDC
00003364111
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ATAZANAVIR SULFATE; COBICISTATApproval Type
New Drug (NDA)
FDA Application
NDA206353FDA Approved
1/29/2015
On Market Since
1/29/2015
Pharmacological Classes
Price Statistics
The NADAC for EVOTAZ 300 MG-150 MG TABLET has been published 555 times since Jun 17, 2015, and over the history we have for it it has risen 15.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $52.0479 per EA |
|---|---|
| All-time high | $52.1041 (Feb 15, 2017) |
| All-time low | $44.9016 (Jul 22, 2015) |
| 52-week high | $52.0479 |
| 52-week low | $51.9394 |
| Median price | $51.9275 |
| Average price | $51.1724 |
| Largest weekly change | +7.9% (Jan 13, 2016) |
| Weeks tracked | 555 |
| Tracking since | Jun 17, 2015 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the atazanavir and cobicistat market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
E.R. Squibb & Sons, L.L.C. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
atazanavir and cobicistat market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cytochrome P450 3A Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EVOTAZ 300 MG-150 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for EVOTAZ 300 MG-150 MG TABLET, manufactured by E.R. Squibb & Sons, L.L.C., is $52.0479 per EA (NDC 00003364111), effective Sep 30, 2026.
How has the price of EVOTAZ 300 MG-150 MG TABLET changed over time?
Over the history we have for it, the NADAC for EVOTAZ 300 MG-150 MG TABLET has risen 15.5%. It has been tracked across 555 weekly CMS publications since Jun 17, 2015.
What are the highest and lowest recorded NADAC prices for EVOTAZ 300 MG-150 MG TABLET?
Since Jun 17, 2015, the NADAC for EVOTAZ 300 MG-150 MG TABLET has ranged from a low of $44.9016 (Jul 22, 2015) to a high of $52.1041 (Feb 15, 2017), with a median of $51.9275 per EA.
Are there cheaper alternatives to EVOTAZ 300 MG-150 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of EVOTAZ 300 MG-150 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures EVOTAZ 300 MG-150 MG TABLET?
EVOTAZ 300 MG-150 MG TABLET (NDC 00003364111) is labeled by E.R. Squibb & Sons, L.L.C., and CMS classifies it as a brand product.